Ryvu Therapeutics (RVU) investor relations material

Executive summary

• Report covers the period from January 1, 2026 to March 31, 2026, prepared under IAS 34.

• Core business is biotechnology R&D, with a focus on oncology and small-molecule therapeutics.

• Company continues as a going concern, supported by strong cash reserves and secured grant revenues.

• Significant events include a new grant agreement for the PERO project and extension of the BioNTech collaboration.

Financial highlights

• Total operating revenue for Q1 2026 was PLN 21,710 thousand, up slightly from PLN 21,034 thousand in Q1 2025.

• Net loss for Q1 2026 was PLN 12,647 thousand, an improvement from a net loss of PLN 25,276 thousand in Q1 2025.

• Cash and cash equivalents at March 31, 2026 were PLN 49,696 thousand, with an additional PLN 33,404 thousand in low-risk investment funds.

• Operating expenses decreased to PLN 34,106 thousand from PLN 48,683 thousand year-over-year.

• Financial income was PLN 2,664 thousand, down from PLN 14,862 thousand in Q1 2025.

Outlook and guidance

• Management expects current cash, investment funds, and secured revenues to support ongoing operations and key R&D programs for at least 12 months.

• The extension of the BioNTech collaboration and new grant funding are expected to support future research activities.